Lung cancer â€" major changes in the American Joint Co cancer staging manual

Ca-A Cancer Journal for Clinicians 67, 138-155 DOI: 10.3322/caac.21390

Citation Report

#	Article	IF	CITATIONS
1	Lung cancer requires multidisciplinary treatment to improve patient survival: A case report. Oncology Letters, 2017, 14, 3035-3038.	0.8	26
2	Esophageal ultrasound (EUS) assessment of T4 status in NSCLC patients. Lung Cancer, 2017, 114, 50-55.	0.9	5
4	Segmentation and classification of lung tumor from 3D CT image using K-means clustering algorithm. , 2017, , .		19
5	Comprehensive Cross-sectional Imaging of the Pulmonary Veins. Radiographics, 2017, 37, 1928-1954.	1.4	44
6	Recent advances in the management of non-small cell lung cancer. F1000Research, 2017, 6, 2110.	0.8	21
7	How to manage patients with subcentimeter non-small cell lung cancer?. Journal of Thoracic Disease, 2017, 9, 4860-4862.	0.6	2
8	Radiomics Approach to Prediction of Occult Mediastinal Lymph Node Metastasis of Lung Adenocarcinoma. American Journal of Roentgenology, 2018, 211, 109-113.	1.0	68
9	Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 412-441.	2.3	432
10	Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 939-947.	1.4	36
11	Long non-coding RNA HNF1A-AS1 promotes cell proliferation and invasion via regulating miR-17-5p in non-small cell lung cancer. Biomedicine and Pharmacotherapy, 2018, 98, 594-599.	2.5	53
12	Prognostic impact of lymphadenectomy on outcomes of sublobar resection for stage IA non–small cell lung cancer â‰⊉Ácm. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 796-805.e4.	0.4	50
13	Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC. Clinical Epigenetics, 2018, 10, 41.	1.8	12
14	The eighth TNM classification for lung cancer—What is next?. Lung Cancer, 2018, 121, 97-98.	0.9	2
15	Prognostic Impact of the Findings on Thin-Section Computed Tomography in stage I lung adenocarcinoma with visceral pleural invasion. Scientific Reports, 2018, 8, 4743.	1.6	13
16	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
17	<i>AFAP1â€AS1</i> : A novel oncogenic long nonâ€coding RNA in human cancers. Cell Proliferation, 2018, 51,	2.4	57
18	Nomogram to Predict Cause-Specific Mortality in Patients With Surgically Resected Stage I Non–Small-Cell Lung Cancer: A Competing Risk Analysis. Clinical Lung Cancer, 2018, 19, e195-e203.	1.1	51
19	Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?. Journal of Thoracic Disease, 2018, 10, S1461-S1467.	0.6	25

		CITATION REPORT	
#	Article	IF	Citations
20	Manejo paliativo del paciente con enfermedad pulmonar avanzada. Medicine, 2018, 12, 3822-383	. 0.0	0
21	Radiation Therapy for Non-Small Cell Lung Cancer in the Twenty-First Century. , 2018, , .		О
22	Video assisted thoracic surgery vs. thoracotomy for locally advanced lung squamous cell carcinon after neoadjuvant chemotherapy. Journal of Cardiothoracic Surgery, 2018, 13, 128.	na 0.4	22
23	A nomogram to predict prognosis in patients undergoing sublobar resection for stage IA non-small-cell lung cancer. Cancer Management and Research, 2018, Volume 10, 6611-6626.	0.9	11
24	CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC). Journal of Clinical Medicine, 7, 303.	2018, 1.0	38
25	Expression profiles of long noncoding RNAs in lung adenocarcinoma. OncoTargets and Therapy, 2 Volume 11, 5383-5390.	018, 1.0	26
26	The 8th lung cancer TNM classification and clinical staging system: review of the changes and clin implications. Quantitative Imaging in Medicine and Surgery, 2018, 8, 709-718.	ical 1.1	170
27	Prognostic ability of new T1 descriptors in the tumour, node and metastasis classification of surgically treated non-small-cell lung cancerâ€. Interactive Cardiovascular and Thoracic Surgery, 2018, 27, 714-719.	0.5	5
28	N2 lung cancer is not all the same: an analysis of different prognostic groupsâ€. Interactive Cardiovascular and Thoracic Surgery, 2018, 27, 720-726.	0.5	13
29	Efficacy of repeated surgery is superior to that of nonâ€surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer. Thoracic Cancer, 2018, 9, 1062-1068.	0.8	13
30	The Impact of the Eighth TNM Classification for Lung Cancer on the Endobronchial Ultrasound Procedure. Journal of Thoracic Oncology, 2018, 13, e119-e120.	0.5	0
31	Survival rates after lobectomy versus sublobar resection for earlyâ€stage right middle lobe nonâ€ cell lung cancer. Thoracic Cancer, 2018, 9, 1026-1031.	small 0.8	11
32	A Novel Bromophenol Derivative BOS-102 Induces Cell Cycle Arrest and Apoptosis in Human A549 Cancer Cells via ROS-Mediated PI3K/Akt and the MAPK Signaling Pathway. Marine Drugs, 2018, 1	9 Lung 2.2 6, 43.	44
34	The prognostic value of multiorgan metastases in patients with non-small cell lung cancer and its variants: a SEER-based study. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1835-	1842. ^{1.2}	39
35	Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis. Acta Biochimica Biophysica Sinica, 2018, 50, 1018-1027.	Et 0.9	21
36	Pathologic T Descriptor of Nonmucinous Lung Adenocarcinomas Now Based on Invasive Tumor Si American Journal of Clinical Pathology, 2018, 150, 499-506.	ze. 0.4	9
37	Reply. Annals of Thoracic Surgery, 2018, 106, 1261.	0.7	0
38	Multiple gastrointestinal metastases of squamous-cell lung cancer. Medicine (United States), 201 e11027.	8, 97, 0.4	11

#	ARTICLE	IF	CITATIONS
39	The prognostic impact of lymph node metastasis in patients with non-small cell lung cancer and distant organ metastasis. Clinical and Experimental Metastasis, 2019, 36, 457-466.	1.7	18
40	Prognosis after wedge resection in patients with 8th edition TNM stage IA1 and IA2 non-small cell lung cancer. Journal of Thoracic Disease, 2019, 11, 2361-2372.	0.6	14
41	The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations. Diagnostic and Interventional Radiology, 2019, 25, 270-279.	0.7	58
42	Comparing clinicopathological features and prognosis of primary pulmonary invasive mucinous adenocarcinoma based on computed tomography findings. Cancer Imaging, 2019, 19, 47.	1.2	27
43	Detection of lymph node metastasis in lung cancer patients using a one-step nucleic acid amplification assay: a single-centre prospective study. Journal of Translational Medicine, 2019, 17, 233.	1.8	10
44	Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution. Advances in Radiation Oncology, 2019, 4, 541-550.	0.6	6
45	Incorporation of a Molecular Prognostic Classifier Improves Conventional Non–Small Cell Lung Cancer Staging. Journal of Thoracic Oncology, 2019, 14, 1223-1232.	0.5	20
46	Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. Journal of Thoracic Oncology, 2019, 14, 1583-1593.	0.5	55
47	Waste not, want not: diagnostic material found in suction syringe aspirate during endobronchial ultrasound guided transbronchial needle aspiration. Journal of Thoracic Disease, 2019, 11, 3270-3275.	0.6	3
48	ROCK1 promotes migration and invasion of nonâ€'smallâ€'cell lung cancer cells through the PTEN/PI3K/FAK pathway. International Journal of Oncology, 2019, 55, 833-844.	1.4	55
49	Survival nomogram for patients with initially diagnosed metastatic non-small-cell lung cancer: a SEER-based study. Future Oncology, 2019, 15, 3395-3409.	1.1	18
50	High Expression of Indoleamine 2, 3-Dioxygenase in Adenosquamous Lung Carcinoma Correlates with Favorable Patient Outcome. Journal of Cancer, 2019, 10, 267-276.	1.2	9
51	Real-world outcomes in patients with unresected stage III non-small cell lung cancer. Medical Oncology, 2019, 36, 24.	1.2	21
52	Long nonâ€ʿcoding RNAâ€ʿneighboring enhancer of FOXA2 inhibits the migration and invasion of small cell lung carcinoma cells by downregulating transforming growth factorâ€Î²1. Oncology Letters, 2019, 17, 4969-4975.	0.8	6
53	Feasibility of nodal classification for nonâ€small cell lung cancer by merging current N categories with the number of involved lymph node stations. Thoracic Cancer, 2019, 10, 1533-1543.	0.8	17
54	Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer. Advances in Therapy, 2019, 36, 2122-2136.	1.3	111
55	<p>Meta-analysis of comparing part-solid and pure-solid tumors in patients with clinical stage IA non-small-cell lung cancer in the eighth edition TNM classification</p> . Cancer Management and Research, 2019, Volume 11, 2951-2961.	0.9	6
56	Management of Locally Advanced Lung Cancer. , 2019, , 57-86.		1

#	Article	IF	CITATIONS
57	Predictors and survival impact of station 4L metastasis in left non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1313-1319.	1.2	8
58	CT-Based Radiomics Model for Predicting Brain Metastasis in Category T1 Lung Adenocarcinoma. American Journal of Roentgenology, 2019, 213, 134-139.	1.0	25
59	Integrated Analysis of Transcriptome and Prognosis Data Identifies FGF22 as a Prognostic Marker of Lung Adenocarcinoma. Technology in Cancer Research and Treatment, 2019, 18, 153303381982731.	0.8	13
60	Prognostic factors in stage IB non-small cell lung cancer according to the 8th edition of the TNM staging system after curative resection. Journal of Thoracic Disease, 2019, 11, 5352-5361.	0.6	13
61	A review of changes to and clinical implications of the eighth TNM classification of hepatobiliary and pancreatic cancers. Japanese Journal of Clinical Oncology, 2019, 49, 1073-1082.	0.6	12
62	Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2019, 14, 482-493.	0.5	81
63	Imaging of Thoracic Malignancies. , 2019, , 101-146.		0
64	The Effect of Resection Margin Distance and Invasive Component Size on Recurrence After Sublobar Resection in Patients With Small (â‰≌ Cm) Lung Adenocarcinoma. World Journal of Surgery, 2020, 44, 990-997.	0.8	9
65	Propensity-Matched Analysis Comparing Survival After Sublobar Resection and Lobectomy for cT1N0 Lung Adenocarcinoma. Annals of Surgical Oncology, 2020, 27, 703-715.	0.7	28
66	Risk Factors for Occult Lymph Node Metastasis in Peripheral Non‣mall Cell Lung Cancer with Invasive Component Size 3Âcm or Less. World Journal of Surgery, 2020, 44, 1658-1665.	0.8	31
67	Surgical Choice for Clinical Stage IA Non-Small Cell Lung Cancer: View From Regional Lymph Node Metastasis. Annals of Thoracic Surgery, 2020, 109, 1079-1085.	0.7	18
68	Mechanism of lung adenocarcinoma spine metastasis induced by CXCL17. Cellular Oncology (Dordrecht), 2020, 43, 311-320.	2.1	16
69	Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepitheliomaâ€like carcinoma. Thoracic Cancer, 2020, 11, 346-352.	0.8	13
70	Multiple Pulmonary Resections for Synchronous and Metachronous Lung Cancer at Two Chinese Centers. Annals of Thoracic Surgery, 2020, 109, 856-863.	0.7	10
71	Lung Cancer Staging. Surgical Pathology Clinics, 2020, 13, 57-71.	0.7	29
72	Radiomic features of primary tumor by lung cancer stage: analysis in BRAF mutated non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1441-1451.	1.3	9
73	Automatic diagnosis for thyroid nodules in ultrasound images by deep neural networks. Medical Image Analysis, 2020, 61, 101665.	7.0	79
74	Clinical impact of the lung tissue transcriptome in a teenager with multifocal invasive mucinous adenocarcinoma—a case report. Translational Lung Cancer Research, 2020, 9, 793-802.	1.3	3

#	Article	IF	CITATIONS
75	Pretreatment systemic inflammation response index (SIRI) is an independent predictor of survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy: a two-center retrospective study. Annals of Translational Medicine, 2020, 8, 1310-1310.	0.7	21
76	Genomic Profiling and Clinicopathological Characteristics of Neuroendocrine Tumors of the Lung in East Asian Patients. In Vivo, 2020, 34, 3375-3385.	0.6	7
77	Identification of MMP1 as a potential gene conferring erlotinib resistance in non-small cell lung cancer based on bioinformatics analyses. Hereditas, 2020, 157, 32.	0.5	10
78	Status of 10 targeted genes of nonâ€small cell lung cancer in eastern China: A study of 884 patients based on <scp>NGS</scp> in a single institution. Thoracic Cancer, 2020, 11, 2580-2589.	0.8	8
79	Evaluation of the Effect of Lymph Node Status on the Survival of Non-Small Cell Lung Cancer Patients With Brain Metastases: Applications of a Novel Grade Prognostic Assessment Score Model Involving N Stage. Frontiers in Oncology, 2020, 10, 563700.	1.3	6
80	Distinguishing multiple lung primaries from intra-pulmonary metastases and treatment implications. Expert Review of Anticancer Therapy, 2020, 20, 985-995.	1.1	6
81	Epigenetic–smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among earlyâ€stage NSCLC patients. Molecular Oncology, 2020, 14, 2759-2774.	2.1	13
82	<p>Tumor Differentiation and EGFR Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery</p> . Cancer Management and Research, 2020, Volume 12, 12549-12556.	0.9	3
83	Ten-Year Experience of Stereotactic Body Radiotherapy at a Single Institution: Impact of Technological Development on the Outcome of Patients With Early Lung Cancer. Technology in Cancer Research and Treatment, 2020, 19, 153303382097916.	0.8	0
84	Prognosis of wide wedge resection in patients with stage IA1 and IA2 lung adenocarcinoma with total tumor size including the lepidic component greater than 2 cm: a single center retrospective study. Journal of Thoracic Disease, 2020, 12, 4731-4741.	0.6	1
85	Association between number of dissected lymph nodes and survival in stage IA non-small cell lung cancer: a propensity score matching analysis. World Journal of Surgical Oncology, 2020, 18, 322.	0.8	11
86	Stratification of Patients With Stage IB NSCLC Based on the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging Manual. Frontiers in Oncology, 2020, 10, 571.	1.3	26
87	Novel eIF4E/eIF4G protein-protein interaction inhibitors DDH-1 exhibits anti-cancer activity in vivo and in vitro. International Journal of Biological Macromolecules, 2020, 160, 496-505.	3.6	8
88	Molecular Diagnostics in Non-Small Cell Lung Carcinoma. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 386-399.	0.8	3
89	Synchronous Pulmonary Adenocarcinomas. American Journal of Clinical Pathology, 2020, 154, 57-69.	0.4	8
90	Is lobe specific lymph node dissection adequate for cN0–1 non-small cell lung cancer?. Journal of Cardiothoracic Surgery, 2020, 15, 46.	0.4	11
91	Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site study. Lung Cancer, 2020, 142, 90-97.	0.9	29
92	The ERK-MNK-eIF4F signaling pathway mediates TPDHT-induced A549Âcell death in vitro and in vivo. Food and Chemical Toxicology, 2020, 137, 111158.	1.8	10

#	Article	IF	CITATIONS
93	Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e159-e170.	1.8	7
94	Current Topics and Practical Considerations of Cytology Practice in Lung Cancer: Reflexions from the Lung Symposium at the 42nd European Congress of Cytology, Malmö, 2019. Acta Cytologica, 2020, 64, 463-470.	0.7	1
95	Clinicopathologic Significance of False-Positive Lymph Node Status on FDG-PET in Lung Cancer. Clinical Lung Cancer, 2021, 22, 218-224.	1.1	9
96	Management guidelines for stage III non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2021, 157, 103144.	2.0	17
97	Esomeprazole overcomes paclitaxelâ€resistance and enhances anticancer effects of paclitaxel by inducing autophagy in A549/Taxol cells. Cell Biology International, 2021, 45, 177-187.	1.4	22
98	FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with <i>RET</i> Gene Mutations or Fusions. Clinical Cancer Research, 2021, 27, 2130-2135.	3.2	84
99	18F-FDG PET-based radiomics model for predicting occult lymph node metastasis in clinical NO solid lung adenocarcinoma. Quantitative Imaging in Medicine and Surgery, 2021, 11, 215-225.	1.1	17
100	Immune landscape and a promising immune prognostic model associated with TP53 in earlyâ€stage lung adenocarcinoma. Cancer Medicine, 2021, 10, 806-823.	1.3	17
101	The high expression of MTH1 and NUDT5 promotes tumor metastasis and indicates a poor prognosis in patients with non-small-cell lung cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118895.	1.9	12
102	Prognostic impact of preoperative FDC-PET positive lymph nodes in lung cancer. International Journal of Clinical Oncology, 2021, 26, 87-94.	1.0	4
103	Validation of the 8th Edition Nodal Staging and Proposal of New Nodal Categories for Future Editions of the TNM Classification of Non-Small Cell Lung Cancer. Annals of Surgical Oncology, 2021, 28, 4510-4516.	0.7	8
104	One to Ten…What's in a Number?. Seminars in Thoracic and Cardiovascular Surgery, 2021, 33, 848-849.	0.4	0
105	Using Novel Statistical Techniques to Accurately Determine the Predictive Dose Range in a Study of Overall Survival after Definitive Radiotherapy for Stage III Non-Small Cell Lung Cancer in Association with Heart Dose. Journal of Cancer Therapy, 2021, 12, 505-529.	0.1	2
106	Improvement of pathological staging system for neuroendocrine tumors of the lung. Annals of Translational Medicine, 2021, 9, 447-447.	0.7	4
107	Is the size of the lepidic component negligible when measuring the size of the tumor to determine the stage of lung adenocarcinoma?. Journal of Thoracic Disease, 2021, 13, 1434-1444.	0.6	2
108	Two different patterns of lung adenocarcinoma with concomitant <i>EGFR</i> mutation and <i>ALK</i> rearrangement. Tumori, 2022, 108, 12-18.	0.6	2
109	Correlation between spread through air spaces (STAS) and other clinicopathological parameters in lung cancer. Pathology Research and Practice, 2021, 220, 153376.	1.0	10
110	Clinical significance of intrapulmonary lymph node dissection in pathological stage IA nonâ€small cell lung cancer: A propensity score matching analysis. Thoracic Cancer, 2021, 12, 1589-1597.	0.8	2

#	Article	IF	CITATIONS
111	Value of Growth/Differentiation Factor 15 in Diagnosis and the Evaluation of Chemotherapeutic Response in Lung Cancer. Clinical Therapeutics, 2021, 43, 747-759.	1.1	6
112	Number of metastases and their response to chemotherapy impact survival of patients with isolated lung metastases from bone-derived sarcoma. BMC Cancer, 2021, 21, 375.	1.1	7
113	Five long non-coding RNAs establish a prognostic nomogram and construct a competing endogenous RNA network in the progression of non-small cell lung cancer. BMC Cancer, 2021, 21, 457.	1.1	9
114	Patient-centered outcomes in non-small-cell lung cancer: a real-world perspective. Future Oncology, 2021, 17, 1721-1733.	1.1	3
115	BAI1 nuclear expression reflects the survival of nonsmoking nonâ€small cell lung cancer patients. Thoracic Cancer, 2021, 12, 1673-1680.	0.8	1
116	Comparison of Lobectomy and Sublobar Resection for Stage IA Elderly NSCLC Patients (≥70 Years): A Population-Based Propensity Score Matching's Study. Frontiers in Oncology, 2021, 11, 610638.	1.3	14
117	The prognostic utility of the histologic subtype of stage I lung adenocarcinoma may be diminished when using only the invasive component to determine tumor size for tumor node metastasis (TNM) staging. Journal of Thoracic Disease, 2021, 13, 2910-2922.	0.6	1
118	Comparison of perioperative and survival outcomes between sublobar resection and lobectomy of patients who underwent a second pulmonary resection. Thoracic Cancer, 2021, 12, 2375-2381.	0.8	1
119	Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer. Modern Pathology, 2021, 34, 1990-1998.	2.9	13
120	Peripheral blood transcriptome heterogeneity and prognostic potential in lung cancer revealed by RNAâ€5eq. Journal of Cellular and Molecular Medicine, 2021, 25, 8271-8284.	1.6	4
121	FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review. Clinical Cancer Research, 2021, 27, 6638-6643.	3.2	35
122	Should we distinguish between intra and extrapericardial pulmonary artery involvement in NSCLC? A multicenter retrospective case-control study. European Journal of Surgical Oncology, 2021, 47, 2982-2988.	0.5	1
123	Dynamic nomograms combining N classification with ratio-based nodal classifications to predict long-term survival for patients with lung adenocarcinoma after surgery: a SEER population-based study. BMC Cancer, 2021, 21, 653.	1.1	8
124	Immunotherapy for locally advanced non-small cell lung cancer: current evidence and future perspectives. Current Challenges in Thoracic Surgery, 0, 3, 25-25.	0.2	0
125	Cumulative experience of the anterior approach in robot-assisted thoracic surgery for lung cancer patients. Journal of Thoracic Disease, 2021, 13, 5487-5495.	0.6	3
127	Computed Tomography Imaging Characteristics. Journal of Computer Assisted Tomography, 2021, Publish Ahead of Print, 964-969.	0.5	0
128	Incidence and survival analyses for occult lung cancer between 2004 and 2015: a population-based study. BMC Cancer, 2021, 21, 1009.	1.1	17
129	Reconsidering the American Joint Committee on Cancer Eighth Edition TNM Staging Manual Classifications for T2b and T3 NSCLC. Journal of Thoracic Oncology, 2021, 16, 1672-1683.	0.5	9

#	Article	IF	Citations
π 130	The effect that pathologic and radiologic interpretation of invasive and non-invasive areas in lung	0.6	2
150	adenocarcinoma has on T-stage and treatment. Annals of Diagnostic Pathology, 2021, 54, 151799.	0.0	2
131	Novel CT Radiomics Nomograms for Prediction of EGFR Mutations and Ki-67 Proliferation Index in Non-Small Cell Lung Cancer: A Multicentre Study. SSRN Electronic Journal, 0, , .	0.4	0
132	Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Translational Lung Cancer Research, 2021, 10, 506-518.	1.3	49
133	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 1965-1976.	2.0	14
134	Comprehensive Study of Surgical Treated Lung Adenocarcinoma with Ground Glass Nodule Component. Medical Science Monitor, 2019, 25, 8492-8498.	0.5	3
135	High-mobility group box 3 (HMCB3) silencing inhibits non-small cell lung cancer development through regulating Wnt/l²-catenin pathway. Biological Chemistry, 2020, 401, 1191-1198.	1.2	16
136	Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses. Aging, 2020, 12, 14244-14270.	1.4	23
137	Molecular profiling identifies prognostic markers of stage IA lung adenocarcinoma. Oncotarget, 2017, 8, 74846-74855.	0.8	7
138	Prediction of pleural invasion using different imaging tools in non-small cell lung cancer. Annals of Translational Medicine, 2019, 7, 33-33.	0.7	12
139	Understanding Clinical Practice and Survival Outcomes in Patients with Unresectable Stage III Non-Small-Cell Lung Cancer in a Single Centre in Quebec. Current Oncology, 2020, 27, 459-466.	0.9	13
140	A nomogram for the prediction of overall survival in patients with stage II and III non‑small cell lung cancer using a population‑based study. Oncology Letters, 2019, 18, 5905-5916.	0.8	18
141	Prognostic Factors in Stage IIB Non-Small Cell Lung Cancer according to the 8th Edition of TNM Staging System. Korean Journal of Thoracic and Cardiovascular Surgery, 2019, 52, 131-140.	0.6	4
142	Different distant metastasis patterns based on tumor size could be found in extensive-stage small cell lung cancer patients: a large, population-based SEER study. PeerJ, 2019, 7, e8163.	0.9	11
143	Previous Extrapulmonary Malignancies Impact Outcomes in Patients With Surgically Resected Lung Cancer. Frontiers in Surgery, 2021, 8, 747249.	0.6	3
144	Radiation Therapy in Non-small-Cell Lung Cancer. , 2019, , 1-55.		0
145	Tumor-node-metastasis staging and treatment patterns of 73,167 patients with lung cancer in Brazil. Jornal Brasileiro De Pneumologia, 2020, 46, e20180251.	0.4	8
148	Dosimetric comparison of helical tomotherapy and hybrid (3DCRT-VMAT) technique for locally advanced non-small cell lung cancer. Journal of Radiotherapy in Practice, 2021, 20, 300-305.	0.2	1
149	The diagnostic value of the combination of carcinoembryonic antigen, squamous cell carcinoma-related antigen, CYFRA 21-1, neuron-specific enolase, tissue polypeptide antigen, and progastrin-releasing peptide in small cell lung cancer discrimination. International Journal of Biological Markers. 2021. 36. 36-44.	0.7	12

#	Article	IF	CITATIONS
150	Survival analysis and factors affecting survival in patients who presented to the medical oncology unit with non-small cell lung cancer. Turkish Journal of Medical Sciences, 2020, 50, 1838-1850.	0.4	12
151	New TNM staging in lung cancer (8th edition) and future perspectives. Journal of Clinical and Translational Research, 0, , .	0.3	3
152	The clinical prognostic factors of patients with stage IB lung adenocarcinoma. Translational Cancer Research, 2021, 10, 4727-4738.	0.4	2
153	The prognostic analysis of lung cancer patients with occult malignant pleural disease at thoracotomy. Translational Cancer Research, 2020, 9, 1689-1697.	0.4	0
154	SMAD‑6, ‑7 and ‑9 are potential molecular biomarkers for the prognosis in human lung cancer. Oncology Letters, 2020, 20, 2633-2644.	0.8	11
155	Evaluation of solid portions in non-small cell lung cancer—the solid part is not always measurable for clinical T factor. Japanese Journal of Clinical Oncology, 2021, 51, 114-119.	0.6	5
156	Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma. JTO Clinical and Research Reports, 2020, 1, 100084.	0.6	2
158	Combined treatment of cholangiocarcinoma with interventional radiofrequency hyperthermia and heat shock protein promoter-mediated HSV-TK gene therapy. American Journal of Cancer Research, 2018, 8, 1595-1603.	1.4	1
160	New TNM staging in lung cancer (8 edition) and future perspectives. Journal of Clinical and Translational Research, 2020, 6, 145-154.	0.3	4
161	Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer. Journal of Clinical and Translational Research, 2021, 7, 185-198.	0.3	1
162	Alterations of the Human Lung and Gut Microbiomes in Non-Small Cell Lung Carcinomas and Distant Metastasis. Microbiology Spectrum, 2021, 9, e0080221.	1.2	28
163	The combination of computed tomography features and circulating tumor cells increases the surgical prediction of visceral pleural invasion in clinical T1NOMO lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 4266-4280.	1.3	7
164	Pathologic and gene expression comparison of CT- screen detected and routinely detected stage I/0 lung adenocarcinoma in NCCN risk-matched cohorts Cancer Treatment and Research Communications, 2021, 29, 100486.	0.7	1
165	The prognosis of small-sized non-small cell lung cancer with visceral pleural invasion after sublobar resection. Translational Cancer Research, 2020, 9, 6431-6443.	0.4	4
166	Consideration of the Optimal Surgical Procedure Based on the Risk of Recurrence in Clinical Stage 0 or IA Lung Adenocarcinoma. Anticancer Research, 2022, 42, 1137-1142.	0.5	1
167	Twice-daily thoracic radiotherapy by intensity-modulated radiation therapy (IMRT) compared with simultaneous integrated boost IMRT (SIB-IMRT) with concurrent chemotherapy for patients with limited-stage small cell lung cancer. A propensity-score matched analysis. Radiotherapy and Oncology, 2022, 172, 140-146.	0.3	2
168	Recent Advances in the Diagnosis and Management of Multiple Primary Lung Cancer. Cancers, 2022, 14, 242.	1.7	13
169	The Relative Survival Impact of Guideline-Concordant Clinical Staging and Stage-Appropriate Treatment of Potentially Curable Non-Small Cell Lung Cancer. Chest, 2022, 162, 242-255.	0.4	4

#	Article	IF	CITATIONS
170	Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations. Cancers, 2022, 14, 832.	1.7	7
171	Prognostic significance of novel inflammatory markers in extensive-stage small-cell lung cancer. Journal of Cancer Research and Therapeutics, 2022, 18, 691.	0.3	7
173	Development and Validation of a Concise Prediction Scoring System for Asian Lung Cancer Patients with <i>EGFR</i> Mutation Before Treatment. Technology in Cancer Research and Treatment, 2022, 21, 153303382210787.	0.8	1
174	Novel PARP Inhibitor DDPF-20 Induces DNA Damage and Inhibits Angiogenesis through the PI3K/Akt/VEGF Pathway. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 2468-2476.	0.9	2
175	Management of bronchopulmonary neuroendocrine tumors. International Journal of Cancer Care and Delivery, 0, , .	0.0	0
176	Sanguinarine Represses the Growth and Metastasis of Non-small Cell Lung Cancer by Facilitating Ferroptosis. Current Pharmaceutical Design, 2022, 28, 760-768.	0.9	16
177	Treatment Modality for Stage IB Peripheral Non-Small Cell Lung Cancer With Visceral Pleural Invasion and â‰9 cm in Size. Frontiers in Oncology, 2022, 12, 830470.	1.3	1
178	Prognostic significance of laterality in lung neuroendocrine tumors. Endocrine, 2022, 76, 733-746.	1.1	8
179	Is Brain MRI Unnecessary for Early-Stage Non–Small Cell Lung Cancer?. Radiology, 2022, 303, 644-645.	3.6	1
180	Factors Associated with Nodal Upstaging in Clinical T1a-bN0M0 Non-Small Cell Lung Cancers. Cancers, 2022, 14, 1277.	1.7	7
181	Do older patients with stage IB non-small-cell lung cancer obtain survival benefits from surgery? A propensity score matching study using SEER data. European Journal of Surgical Oncology, 2022, 48, 1954-1963.	0.5	2
182	An Effective Hypoxia-Related Long Non-Coding RNA Assessment Model for Prognosis of Lung Adenocarcinoma. Frontiers in Genetics, 2022, 13, 768971.	1.1	6
183	The Value of Dysregulated LncRNAs on Clinicopathology and Survival in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Genetics, 2022, 13, 821675.	1.1	1
184	Real-World Perspectives From Surgeons and Oncologists on Resectability Definition and Multidisciplinary Team Discussion of Stage III NSCLC in People's Republic of China, Hong Kong, and Macau: A Physician Survey. JTO Clinical and Research Reports, 2022, 3, 100308.	0.6	0
185	Development and validation of novel radiomics-based nomograms for the prediction of EGFR mutations and Ki-67 proliferation index in non-small cell lung cancer. Quantitative Imaging in Medicine and Surgery, 2022, 12, 2658-2671.	1.1	11
186	A Novel Prognostic and Predictive Signature for Lung Adenocarcinoma Derived from Combined Hypoxia and Infiltrating Immune Cell-Related Genes in TCGA Patients. International Journal of General Medicine, 2021, Volume 14, 10467-10481.	0.8	2
189	Vascular Invasion Identifies the Most Aggressive Histologic Subset of Stage I Lung Adenocarcinoma: Implications for Adjuvant Therapy. SSRN Electronic Journal, 0, , .	0.4	0
191	The Difference and Significance of Parietal Pleura Invasion and Rib Invasion in Pathological T Classification With Non-Small Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 878482.	1.3	5

# 192	ARTICLE Exosomal LncRNA RP5-977B1 as a novel minimally invasive biomarker for diagnosis and prognosis in non-small cell lung cancer. International Journal of Clinical Oncology, 2022, 27, 1013-1024.	IF 1.0	CITATIONS
195	Cost-Effectiveness of Lung Cancer Screening Using Low-Dose Computed Tomography Based on Start Age and Interval in China: Modeling Study. JMIR Public Health and Surveillance, 2022, 8, e36425.	1.2	6
196	Overexpression of ERCC6L correlates with poor prognosis and confers malignant phenotypes of lung adenocarcinoma. Oncology Reports, 2022, 48, .	1.2	2
198	Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors—Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?. Cancers, 2022, 14, 3323.	1.7	0
199	Vascular invasion identifies the most aggressive histologic subset of stage I lung adenocarcinoma: Implications for adjuvant therapy. Lung Cancer, 2022, 171, 82-89.	0.9	5
200	Comparison of 6th, 7th, and 8th editions of the TNM staging in non-small cell lung cancer patients: Validation of the 8th edition of TNM staging. Turkish Journal of Thoracic and Cardiovascular Surgery, 2022, 30, 395-403.	0.2	1
201	The value of CT radiomics features to predict visceral pleural invasion in â‰ 8 cm peripheral type early non-small cell lung cancer. Journal of X-Ray Science and Technology, 2022, 30, 1115-1126.	0.7	4
202	The Effect of Sarcopenia and Metabolic PET-CT Parameters on Survival in Locally Advanced Non-Small Cell Lung Carcinoma. Nutrition and Cancer, 2023, 75, 286-295.	0.9	1
203	Prognostic significance of TG/HDL-C and non-HDL-C/HDL-C ratios in patients with non-small cell lung cancer: a retrospective study. Journal of International Medical Research, 2022, 50, 030006052211172.	0.4	3
204	Small cell lung cancer with relapsing polychondritis: A report of one case and the review of literature. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211209.	1.0	0
205	Diagnostic Applications of Nuclear Medicine: Lung and Mediastinal Tumors. , 2022, , 743-809.		0
206	What's the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients. Frontiers in Endocrinology, 0, 13, .	1.5	7
207	Systematic endoscopic staging of mediastinum to determine impact on radiotherapy for locally advanced lung cancer (SEISMIC): protocol for a prospective single arm multicentre interventional study. BMC Pulmonary Medicine, 2022, 22, .	0.8	2
208	Effect of Covid-19 pandemic on patients undergoing definitive chemoradiotherapy. Cumhuriyet Medical Journal, 0, , .	0.1	0
209	Development and validation of a prognostic nomogram for early stage non-small cell lung cancer: a study based on the SEER database and a Chinese cohort. BMC Cancer, 2022, 22, .	1.1	3
210	Role of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer in the COVID-19 Pandemic. Cureus, 2022, , .	0.2	0
211	The Clinical and Prognostic Characteristics of Primary Salivary Gland-Type Carcinoma in the Lung: A Population-Based Study. Cancers, 2022, 14, 4668.	1.7	5
212	Mediastinal lymph node evaluation, especially at station 4L, in left upper lobe lung cancer. Journal of Thoracic Disease, 2022, 14, 3321-3334.	0.6	2

#	Article	IF	CITATIONS
213	Femoral head metastases from primary mucinous lung adenocarcinoma with left hip pain: A case report and literature review. Frontiers in Surgery, 0, 9, .	0.6	0
214	PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma. Frontiers in Immunology, 0, 13, .	2.2	4
215	Automated 3D segmentation of the aorta and pulmonary artery for predicting outcomes after thoracoscopic lobectomy in lung cancer patients. Frontiers in Oncology, 0, 12, .	1.3	0
216	Can quantitative peritumoral CT radiomics features predict the prognosis of patients with non-small cell lung cancer? A systematic review. European Radiology, 2023, 33, 2105-2117.	2.3	14
217	Immune cell-lipoprotein imbalance as a marker for early diagnosis of non-small cell lung cancer metastasis. Frontiers in Oncology, 0, 12, .	1.3	0
218	Radiomics combined with clinical features in distinguishing non-calcifying tuberculosis granuloma and lung adenocarcinoma in small pulmonary nodules. PeerJ, 0, 10, e14127.	0.9	2
219	Recent advances in postoperative pulmonary rehabilitation of patients with non‑small cell lung cancer (Review). International Journal of Oncology, 2022, 61, .	1.4	4
220	MiR-142-3p as an Indicator of OSA Severity Predicts Prognosis in Lung Adenocarcinoma with OSA. Nature and Science of Sleep, 0, Volume 14, 2047-2054.	1.4	1
221	A Study on the Availability of Survival Analysis of Lung Cancer Patients Using Synthetic Data. Journal of Health Informatics and Statistics, 2022, 47, 279-289.	0.1	0
222	Molecular Detection of Lymph Node Metastases in Lung Cancer Patients Using the One-Step Nucleic Acid Amplification Method:Clinical Significance and Prognostic Value. Cells, 2022, 11, 4010.	1.8	0
223	Genomic Profiling With Large-Scale Next-Generation Sequencing Panels Distinguishes Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases. Modern Pathology, 2023, 36, 100047.	2.9	4
224	Derived Neutrophil-Lymphocyte Ratio and C-Reactive Protein as Prognostic Factors for Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy. Diagnostics, 2023, 13, 313.	1.3	3
225	The oncologic efficacy of extended thoracic resections. Journal of Surgical Oncology, 2023, 127, 288-295.	0.8	3
226	Updates in pathology and molecular diagnostics to inform the evolving landscape of thoracic surgery and oncology. Journal of Surgical Oncology, 2023, 127, 244-257.	0.8	1
227	Anti-Programmed Death Receptor 1 Signalling Immunotherapy as a Part of Curative Intent Strategies for Stages I-III Non-Small Cell Lung Cancer. European Medical Journal Respiratory, 0, , 109-116.	1.0	1
228	A novel <scp>NGS</scp> â€based diagnostic algorithm for classifying multifocal lung adenocarcinomas in <scp>pNOMO</scp> patients. Journal of Pathology: Clinical Research, 0, , .	1.3	2
229	Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers. Translational Lung Cancer Research, 2022, 11, 2364-2381.	1.3	5
230	A Nomogram Based on Atelectasis/Obstructive Pneumonitis Could Predict the Metastasis of Lymph Nodes and Postoperative Survival of Pathological N0 Classification in Non-small Cell Lung Cancer Patients. Biomedicines, 2023, 11, 333.	1.4	4

#	Article	IF	CITATIONS
231	Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer. BMC Cancer, 2023, 23, .	1.1	1
232	Stenotrophomonas maltophilia promotes lung adenocarcinoma progression by upregulating histone deacetylase 5. Frontiers in Microbiology, 0, 14, .	1.5	2
233	Prognostic Value of Tumor Size in Gastric Cancer: A Retrospective Cohort Study Based on SEER Database. International Journal of Surgical Pathology, 2023, 31, 1273-1282.	0.4	1
234	Bleeding-related re-exploration following pulmonary resection: a report of a single-center experience. Journal of Cancer Research and Clinical Oncology, 2023, 149, 6841-6848.	1.2	2
235	Evaluation of the relationship of the T and M stage with the erector spinae muscle area in male lung cancer patients. Aging Male, 2023, 26, .	0.9	0
236	Gastroparesis after video-assisted thoracic surgery: A case report. World Journal of Clinical Cases, 0, 11, 1862-1868.	0.3	2
237	Construction and validation of a prognostic model based on ten signature cell cycle-related genes for early-stage lung squamous cell carcinoma. Cancer Biomarkers, 2023, 36, 313-326.	0.8	0
238	How Natural Language Processing Can Aid With Pulmonary Oncology Tumor Node Metastasis Staging From Free-Text Radiology Reports: Algorithm Development and Validation. JMIR Formative Research, 0, 7, e38125.	0.7	3
239	Predictability and Utility of Contrast-Enhanced CT on Occult Lymph Node Metastasis for Patients with Clinical Stage IA-IIA Lung Adenocarcinoma: A Double-Center Study. Academic Radiology, 2023, 30, 2870-2879.	1.3	1
240	Reconsidering the T category for the T3 non-small cell lung cancer with additional tumor nodules in the same lobe: A population-based study. Frontiers in Oncology, 0, 13, .	1.3	1
243	CoADS: Cross attention based dual-space graph network for survival prediction of lung cancer using whole slide images. Computer Methods and Programs in Biomedicine, 2023, 236, 107559.	2.6	2
268	Surgical Treatment for Lung Cancer. , 2023, , 1-11.		0
277	Lung and Mediastinal Cancer. , 2023, , 107-155.		0
279	LNMER-Net: A Metabolically Enhanced Lymph Node Metastasis Recognition Model Based on Lung Lymph Nodes and Microenvironment. Lecture Notes in Electrical Engineering, 2024, , 11-22.	0.3	0